Prescription ·Strong evidence ·Reviewed May 2026
Dapagliflozin is an SGLT2 inhibitor approved for type 2 diabetes, heart failure (with reduced or preserved ejection fraction), and chronic kidney disease. The DAPA-HF and DAPA-CKD trials established its broad cardiorenal benefits, making it one of the first diabetes medications approved for heart failure independent of diabetes status.
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 0.5–0.8%, heart failure hospitalization reduction (dapa-hf: 26% rrr), slows progression of chronic kidney disease (dapa-ckd). 10 sources indexed (2023–2025), with 3 interaction records on file.
Core mechanism
Selectively inhibits SGLT2 in the proximal renal tubule, blocking reabsorption of approximately 50–80 g of glucose per day and causing glycosuria. This insulin-independent mechanism lowers blood glucose while promoting caloric loss, osmotic diuresis, and natriuresis. Additional benefits include reduced intraglomerular pressure, improved tubuloglomerular feedback, and decreased cardiac preload and afterload.
Can be taken with or without food, preferably in the morning.
Dapagliflozin and berberine both lower blood glucose through independent mechanisms. Combined use may increase hypoglycemia risk.
Recommendation: Monitor blood glucose when combining. Low risk when used alone but relevant in multi-drug regimens.
Dapagliflozin reduces blood glucose by promoting urinary glucose excretion, and chromium improves insulin sensitivity. On dapagliflozin alone the hypoglycemia risk is low, but adding chromium to a regimen that already contains insulin or a sulfonylurea can produce symptomatic lows.
Recommendation: If dapagliflozin is your only diabetes medication, chromium can be added with home glucose monitoring during the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether the other agent should be reduced before starting chromium.
Alpha-lipoic acid improves insulin sensitivity and dapagliflozin causes urinary glucose excretion. Dapagliflozin alone rarely causes hypoglycemia, but additive effects matter when ALA is added on top of insulin or a sulfonylurea. ALA has also been associated with insulin autoimmune syndrome (Hirata syndrome) producing severe spontaneous hypoglycemia.
Recommendation: If dapagliflozin is your only diabetes medication, ALA can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether the other agent needs a dose reduction first.
Numbered references. Citations throughout the page link here.
Dahal K, Rawal L, Shah S et al.. Efficacy and outcomes of dapagliflozin in diabetic nephropathy: A systematic review and meta-analysis. Medicine. 2025
Raja A, Dogar ME, Raja S et al.. Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness. BMC cardiovascular disorders. 2024
Addo B, Agyeman W, Ibrahim S et al.. Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2024
Ali AE, Mazroua MS, ElSaban M et al.. Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Global heart. 2023
Iyer N, Hussein S, Singareddy S et al.. Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality. Cureus. 2023
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack